Sponsor: AbbVie, Inc
Sponsor Study ID: M16-109
Study Title: A Phase 2 Open Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis (REFINE)
CTO #: 103309
NCT Number: NCT03222609
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Other Hematopoietic
Study Objectives: This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.